|
1) Vaziri ND, Zhou XJ, Naqvi F, et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol. 1996; 271: E113 -22
|
|
|
|
2) Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol. 1994; 4: 1874-8
|
|
|
|
|
|
3) Nakamura Y, Komatsu N, Nakauchi H. A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 1992; 257: 1138-41
|
|
|
|
|
4) Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964-7
|
|
|
|
|
|
5) Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593-600
|
|
|
|
|
|
6) Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353: 999-1007
|
|
|
|
|
|
7) 日本透析医学会統計調査委員会. 図説わが国の慢性透析療法の現況 (2006年12月31日現在). 東京: 日本透析医学会; 2007. p. 31
|
|
|
|
|
|
8) Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant. 1995; 10 Suppl 2: 74-9
|
|
|
|
|
|
9) Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol. 2000; 20: 375-81
|
|
|
|
|
|
10) Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol. 1991; 261: E642-6
|
|
|
|
|
|
11) Barrett JD, Zhang Z, Zhu JH, et al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens. 1998; 16: 1749-57
|
|
|
|
|
|
12) Hand MF, Haynes WG, Johnstone HA, et al. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int. 1995; 48: 806-13
|
|
|
|
|
|
13) Tojo A, Doumoto M, Oka K, et al. Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hyperten-sive rats. Am J Physiol. 1996; 270: R744-8
|
|
|
|
|
|
14) Takahashi K, Totsune K, Imai Y, et al. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci. 1993; 84: 47-50
|
|
|
|
|
|
15) Bode-Boger SM, Boger RH, Kuhn M, et al. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996; 50: 1255-61
|
|
|
|
|
|
16) Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythro-poietin receptor and nitric oxide production by endothelial cells. Blood. 2004; 104: 2073-80
|
|
|
|
|
|
17) Banerjee D, Rodriguez M, Nag M, et al. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int. 2000; 57: 1895-904
|
|
|
|
|
|
18) Scalera F, Kielstein JT, Martens-Lobenhoffer J, et al. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of imethylarginine dimethylaminohydrolase. J Am Soc Nephrol. 2005; 16: 892-8
|
|
|
|
|
|
19) Wang XQ, Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension. 1999; 33: 894-9
|
|
|
|
|
|
20) Akimoto T, Kusano E, Fujita N, et al. Erythropoietin modulates angiotensin II- or noradrenaline-induced Ca(2＋) mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant. 2001; 16: 491-9
|
|
|
|
|
|
21) Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med. 2003; 228: 1-14
|
|
|
|
|
|
22) D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989; 57: 277-85
|
|
|
|
|
|
23) Winkelmann JC, Penny LA, Deaven LL, et al. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood. 1990; 76: 24-30
|
|
|
|
|
|
24) Jones SS, D'Andrea AD, Haines LL, et al. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood. 1990; 76: 31-5
|
|
|
|
|
|
25) Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003; 59: 538-48
|
|
|
|
|
|
26) Shimizu R, Komatsu N, Miura Y. Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelo-dysplastic syndrome. Exp Hematol. 1999; 27: 229-33
|
|
|
|
|
|
27) Baynes RD, Reddy GK, Shih YJ, et al. Serum form of the erythropoietin receptor identified by a sequence-specific peptide antibody. Blood. 1993; 82: 2088-95
|
|
|
|
|
|
28) Yoshida S, Bessho M, Sakate K, et al. Lack of relationship between soluble erythropoietin receptor levels and erythroid parameters in anemic patients. Blood. 1996; 88: 3246-7
|
|
|
|
|
|
29) 坂口美佳, 前田裕弘, 内木義人, 他. 腎性貧血における可溶性エリスロポエチンレセプターの関与の可能性. 日本腎臓学会誌. 2002; 44: 524-9
|
|
|
|
|
30) Fliser D, Bahlmann FH, Degroot K, et al. Mechanisms of disease: erythropoietin?an old hormone with a new mission？ Nat Clin Pract Cardiovasc Med. 2006; 3: 563-72
|
|
|
|
|
|
31) Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990; 87: 5978-82
|
|
|
|
|
|
32) Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002; 106: 2973-9
|
|
|
|
|
|
33) Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol. 2007; 150: 839-50
|
|
|
|
|
|
34) Zhande R, Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-inde-pendent upregulation of Bcl-xL. Am J Physiol. Heart Circ Physiol. 2007; 292: H2467-74
|
|
|
|
|
|
35) Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic pheno-type in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999; 93: 2627-36
|
|
|
|
|
|
36) Nakano M, Satoh K, Fukumoto Y, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007; 100: 662-9
|
|
|
|
|
|
37) Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005; 353: 782-92
|
|
|
|
|
|
38) Santhanam AV, Smith LA, Akiyama M, et al. Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 2005; 36: 2731-7
|
|
|
|
|
|
39) Lee ST, Chu K, Sinn DI, et al. Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J Neurochem. 2006; 96: 1728-39
|
|
|
|
|
|
40) Urao N, Okigaki M, Yamada H, et al. Erythro-poietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neo-intimal hyperplasia. Circ Res. 2006; 98: 1405-13
|
|
|
|
|
|
41) Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399: 597-601
|
|
|
|
|
|
42) Dimmeler S, Fleming I, Fisslthaler B, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999; 399: 601-5
|
|
|
|
|
|
43) Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun. 2003; 307: 999-1007
|
|
|
|
|